Literature DB >> 3600768

The glycoprotein encoded by the X-linked chronic granulomatous disease locus is a component of the neutrophil cytochrome b complex.

M C Dinauer, S H Orkin, R Brown, A J Jesaitis, C A Parkos.   

Abstract

The bacteriocidal capacity of phagocytic cells is impaired in X-linked chronic granulomatous disease (X-CGD), a disorder characterized by the absence of functional plasma-membrane-associated NADPH oxidase. The components of this oxidase system, their correspondence with specific genetic loci, and the primary protein defect in X-CGD remain incompletely defined. We recently reported cloning of the putative X-CGD gene on the basis of DNA linkage. To identify the predicted protein in vivo, antibodies were raised to a synthetic peptide derived from the complementary DNA sequence and to a fusion protein produced in Escherichia coli. In Western blots antisera detect a neutrophil protein of relative molecular mass in 90,000 (90K) that is absent in X-CGD patients. Antisera also react with the larger component of cytochrome b recently purified from neutrophil plasma membranes as a complex of glycosylated 90K and non-glycosylated 22K polypeptides. Based on our identification of the X-CGD protein in vivo, we propose that one of its critical roles is to interact with the 22K species to form a functional cytochrome b complex.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3600768     DOI: 10.1038/327717a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  102 in total

1.  Localization of Nox2 N-terminus using polyclonal antipeptide antibodies.

Authors:  Marie-Hélène Paclet; Lydia M Henderson; Yannick Campion; Françoise Morel; Marie-Claire Dagher
Journal:  Biochem J       Date:  2004-09-15       Impact factor: 3.857

Review 2.  Assembly of the phagocyte NADPH oxidase.

Authors:  William M Nauseef
Journal:  Histochem Cell Biol       Date:  2004-08-04       Impact factor: 4.304

3.  Isolation and characterization of grancalcin, a novel 28 kDa EF-hand calcium-binding protein from human neutrophils.

Authors:  C G Teahan; N F Totty; A W Segal
Journal:  Biochem J       Date:  1992-09-01       Impact factor: 3.857

Review 4.  The electron transport chain of the microbicidal oxidase of phagocytic cells and its involvement in the molecular pathology of chronic granulomatous disease.

Authors:  A W Segal
Journal:  J Clin Invest       Date:  1989-06       Impact factor: 14.808

5.  Coregulation of NADPH oxidase activation and phosphorylation of a 48-kD protein(s) by a cytosolic factor defective in autosomal recessive chronic granulomatous disease.

Authors:  S E Caldwell; C E McCall; C L Hendricks; P A Leone; D A Bass; L C McPhail
Journal:  J Clin Invest       Date:  1988-05       Impact factor: 14.808

6.  A missense mutation in the neutrophil cytochrome b heavy chain in cytochrome-positive X-linked chronic granulomatous disease.

Authors:  M C Dinauer; J T Curnutte; H Rosen; S H Orkin
Journal:  J Clin Invest       Date:  1989-12       Impact factor: 14.808

7.  Superoxide generation is inhibited by phospholipase A2 inhibitors. Role for phospholipase A2 in the activation of the NADPH oxidase.

Authors:  L M Henderson; J B Chappell; O T Jones
Journal:  Biochem J       Date:  1989-11-15       Impact factor: 3.857

8.  A tandem activity-based sensing and labeling strategy enables imaging of transcellular hydrogen peroxide signaling.

Authors:  Hidefumi Iwashita; Erika Castillo; Marco S Messina; Raymond A Swanson; Christopher J Chang
Journal:  Proc Natl Acad Sci U S A       Date:  2021-03-02       Impact factor: 11.205

Review 9.  Mechanisms for the activation/electron transfer of neutrophil NADPH-oxidase complex and molecular pathology of chronic granulomatous disease.

Authors:  S Umeki
Journal:  Ann Hematol       Date:  1994-06       Impact factor: 3.673

10.  A point mutation in gp91-phox of cytochrome b558 of the human NADPH oxidase leading to defective translocation of the cytosolic proteins p47-phox and p67-phox.

Authors:  J H Leusen; M de Boer; B G Bolscher; P M Hilarius; R S Weening; H D Ochs; D Roos; A J Verhoeven
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.